Investigation of the In Vitro and In Vivo efficiency of RM-532-105, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, in LAPC-4 prostate cancer cell and tumor models

• Lucie Carolle Kenmogne,

  Affiliation Laboratory of Medicinal Chemistry, CHU de Québec - Research Center (CHUL, T4), Québec, Québec, Canada

  ⨯
• Jenny Roy,

  Affiliation Laboratory of Medicinal Chemistry, CHU de Québec - Research Center (CHUL, T4), Québec, Québec, Canada

  ⨯
• René Maltais,

  Affiliation Laboratory of Medicinal Chemistry, CHU de Québec - Research Center (CHUL, T4), Québec, Québec, Canada

  ⨯
• Mélanie Rouleau,

  Affiliation CHU de Québec - Research Center, Axe Cancer, Québec, Québec, Canada

  ⨯
• Bertrand Neveu,

  Affiliation CHU de Québec - Research Center, Axe Cancer, Québec, Québec, Canada

  ⨯
• Frédéric Pouliot,

  Affiliations CHU de Québec - Research Center, Axe Cancer, Québec, Québec, Canada, Department of Surgery, Faculty of Medicine, Université Laval, Québec, Québec, Canada

  ⨯
• Donald Poirier

  * E-mail: donald.poirier@crchul.ulaval.ca

  Affiliations Laboratory of Medicinal Chemistry, CHU de Québec - Research Center (CHUL, T4), Québec, Québec, Canada, Department of Molecular Medicine, Faculty of Medicine, Université Laval, Québec, Québec, Canada

  ⨯